{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-034811","form_type":"8-K","ticker":"ELAB","cik":"0001840563","company_name":"PMGC Holdings Inc.","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.068769+00:00","generated_at":"2026-05-23T07:17:28.561085+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PMGC subsidiary Northstrive gets FDA support for IND submission of EL-22 with GLP-1 for obesity","bullets":["FDA agreed pharmacology studies support EL-22 activity and nonclinical studies appear adequate for safety/activity in overweight/obese humans.","Phase 1 and completed nonclinical data deemed adequate to allow initiation of a proposed Phase 2 clinical trial.","Northstrive aims to file IND in 2025 and start Phase 2 trial evaluating EL-22 combined with GLP-1 receptor agonists.","EL-22 is a patent-pending engineered probiotic designed to express myostatin, targeting muscle preservation during weight loss.","Preclinical data in mdx mice showed significant physiological and functional improvements; Phase 1 in South Korea showed good tolerability."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-034811","json":"https://secwatch.observer/filing/0001213900-25-034811.json","markdown":"https://secwatch.observer/filing/0001213900-25-034811.md","text":"https://secwatch.observer/filing/0001213900-25-034811.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840563/000121390025034811/0001213900-25-034811-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840563/000121390025034811/ea0239158-8k_pmgc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:17:28.561085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}